BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 12066193)

  • 1. Assessment of Glut-1 expression in cholangiocarcinoma, benign biliary lesions and hepatocellular carcinoma.
    Zimmerman RL; Fogt F; Burke M; Murakata LA
    Oncol Rep; 2002; 9(4):689-92. PubMed ID: 12066193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms.
    Abe N; Watanabe T; Izumisato Y; Suzuki Y; Masaki T; Mori T; Sugiyama M; Fusco A; Atomi Y
    J Gastroenterol; 2003; 38(12):1144-9. PubMed ID: 14714251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mixed hepatocellular-cholangiocarcinoma may derive from "hepatogones".
    Hunt JP; Varnholt H
    Hepatobiliary Pancreat Dis Int; 2008 Feb; 7(1):105; author reply 105-6. PubMed ID: 18234649
    [No Abstract]   [Full Text] [Related]  

  • 4. Diagnostic utility of GLUT1 in the differential diagnosis of liver carcinomas.
    Roh MS; Jeong JS; Kim YH; Kim MC; Hong SH
    Hepatogastroenterology; 2004; 51(59):1315-8. PubMed ID: 15362741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A subgroup of intrahepatic cholangiocarcinoma with an infiltrating replacement growth pattern and a resemblance to reactive proliferating bile ductules: 'bile ductular carcinoma'.
    Kozaka K; Sasaki M; Fujii T; Harada K; Zen Y; Sato Y; Sawada S; Minato H; Matsui O; Nakanuma Y
    Histopathology; 2007 Sep; 51(3):390-400. PubMed ID: 17553067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined hepatocellular carcinoma and cholangiocarcinoma with components of mucinous carcinoma arising in a cirrhotic liver.
    Morita D; Kagata Y; Ogata S; Tsuda H; Hatsuse K; Mochizuki H; Matsubara O
    Pathol Int; 2006 Apr; 56(4):222-6. PubMed ID: 16634969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The utility of keratin 903 as a new prognostic marker in mass-forming-type intrahepatic cholangiocarcinoma.
    Aishima S; Asayama Y; Taguchi K; Sugimachi K; Shirabe K; Shimada M; Sugimachi K; Tsuneyoshi M
    Mod Pathol; 2002 Nov; 15(11):1181-90. PubMed ID: 12429797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative immunohistochemical expression of p63 in human cholangiocarcinoma and hepatocellular carcinoma.
    Ramalho FS; Ramalho LN; Della Porta L; Zucoloto S
    J Gastroenterol Hepatol; 2006 Aug; 21(8):1276-80. PubMed ID: 16872309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocarcinoma-intestine-pancreas/pancreatic associated protein (HIP/PAP) is expressed and secreted by proliferating ductules as well as by hepatocarcinoma and cholangiocarcinoma cells.
    Christa L; Simon MT; Brezault-Bonnet C; Bonte E; Carnot F; Zylberberg H; Franco D; Capron F; Roskams T; Bréchot C
    Am J Pathol; 1999 Nov; 155(5):1525-33. PubMed ID: 10550309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas.
    Somorácz A; Tátrai P; Horváth G; Kiss A; Kupcsulik P; Kovalszky I; Schaff Z
    Hum Pathol; 2010 Sep; 41(9):1310-9. PubMed ID: 20471664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
    Patsenker E; Wilkens L; Banz V; Osterreicher CH; Weimann R; Eisele S; Keogh A; Stroka D; Zimmermann A; Stickel F
    J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different expression of glucose transporters in the progression of intrahepatic cholangiocarcinoma.
    Kubo Y; Aishima S; Tanaka Y; Shindo K; Mizuuchi Y; Abe K; Shirabe K; Maehara Y; Honda H; Oda Y
    Hum Pathol; 2014 Aug; 45(8):1610-7. PubMed ID: 24824030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification.
    Akiba J; Nakashima O; Hattori S; Tanikawa K; Takenaka M; Nakayama M; Kondo R; Nomura Y; Koura K; Ueda K; Sanada S; Naito Y; Yamaguchi R; Yano H
    Am J Surg Pathol; 2013 Apr; 37(4):496-505. PubMed ID: 23388123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A histopathological study on combined hepatocellular and cholangiocarcinoma: cholangiocarcinoma component is originated from hepatocellular carcinoma.
    Wakasa T; Wakasa K; Shutou T; Hai S; Kubo S; Hirohashi K; Umeshita K; Monden M
    Hepatogastroenterology; 2007 Mar; 54(74):508-13. PubMed ID: 17523309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the expression of agrin, a basement membrane heparan sulfate proteoglycan, in cholangiocarcinoma and hepatocellular carcinoma.
    Batmunkh E; Tátrai P; Szabó E; Lódi C; Holczbauer A; Páska C; Kupcsulik P; Kiss A; Schaff Z; Kovalszky I
    Hum Pathol; 2007 Oct; 38(10):1508-15. PubMed ID: 17640714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α-Fetoprotein-producing gastric carcinoma and combined hepatocellular and cholangiocarcinoma show similar morphology but different histogenesis with respect to SALL4 expression.
    Ikeda H; Sato Y; Yoneda N; Harada K; Sasaki M; Kitamura S; Sudo Y; Ooi A; Nakanuma Y
    Hum Pathol; 2012 Nov; 43(11):1955-63. PubMed ID: 22516245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic features of patients with intrahepatic cholangiocarcinoma who are seropositive for alpha-fetoprotein-L3 and those with combined hepatocellular and cholangiocarcinoma.
    Okuda H; Shiratori K; Yamamoto M; Takasaki K; Nakano M
    J Gastroenterol Hepatol; 2006 May; 21(5):869-73. PubMed ID: 16704538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expression of cytokeratins 7, 19, and 20 in primary and metastatic carcinomas of the liver.
    Maeda T; Kajiyama K; Adachi E; Takenaka K; Sugimachi K; Tsuneyoshi M
    Mod Pathol; 1996 Sep; 9(9):901-9. PubMed ID: 8878022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinicopathologic features and diagnosis of mixed type hepatocellular carcinoma].
    Lu J; Lin Z; Yuan S
    Zhonghua Zhong Liu Za Zhi; 1995 May; 17(3):208-11. PubMed ID: 7656828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [In vivo proton magnetic resonance spectroscopy of hepatocellular carcinoma and cholangiocarcinoma].
    Dong AS; Tian JM; Lu JP; Zuo CJ; Wang L; Wang J
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Apr; 31(2):151-4. PubMed ID: 19507591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.